Search research articles
Contact Us
Filters
Showing results (171-180 of 185) with videos related to
Page
of 19
Sort By:
Research Square
|
August 30, 2023
Tumor cell p38 inhibition to overcome immunotherapy resistance
Jason J Luke, Rebekah E Dadey, Ryan C Augustin, et al.
Lancet (London, England)
|
April 3, 2022
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
Jason J Luke, Piotr Rutkowski, Paola Queirolo, et al.
Cancer Research Communications
|
November 26, 2025
Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors
Benjamin T Cooper, Wade T Iams, David B Page, et al.
Research Square
|
December 23, 2024
Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers
Brandon M Lehrich, Evan R Delgado, Tyler M Yasaka, et al.
Nature Medicine
|
October 19, 2023
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial
Jason J Luke, Manish R Patel, George R Blumenschein, et al.
Lancet (London, England)
|
January 21, 2024
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
Jeffrey S Weber, Matteo S Carlino, Adnan Khattak, et al.
Cancer Discovery
|
November 17, 2019
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
Lawrence Fong, Andrew Hotson, John D Powderly, et al.
Cancer Cell
|
September 11, 2020
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
Catherine S Grasso, Jennifer Tsoi, Mykola Onyshchenko, et al.
Nature Medicine
|
April 9, 2025
Autologous T cell therapy for PRAME<sup>+</sup> advanced solid tumors in HLA-A*02<sup>+</sup> patients: a phase 1 trial
Martin Wermke, Dejka M Araujo, Manik Chatterjee, et al.
Cancer
|
October 29, 2025
Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938)
Liza C Villaruz, Jingxiao Jin, Hong Wang, et al.
Page
of 19
Search research articles
Search
Showing results (171-180 of 185) with videos related to
Sort By:
Page
of 19
Research Square
|
August 30, 2023
Tumor cell p38 inhibition to overcome immunotherapy resistance
Jason J Luke, Rebekah E Dadey, Ryan C Augustin, et al.
Lancet (London, England)
|
April 3, 2022
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
Jason J Luke, Piotr Rutkowski, Paola Queirolo, et al.
Cancer Research Communications
|
November 26, 2025
Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors
Benjamin T Cooper, Wade T Iams, David B Page, et al.
Research Square
|
December 23, 2024
Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers
Brandon M Lehrich, Evan R Delgado, Tyler M Yasaka, et al.
Nature Medicine
|
October 19, 2023
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial
Jason J Luke, Manish R Patel, George R Blumenschein, et al.
Lancet (London, England)
|
January 21, 2024
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
Jeffrey S Weber, Matteo S Carlino, Adnan Khattak, et al.
Cancer Discovery
|
November 17, 2019
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
Lawrence Fong, Andrew Hotson, John D Powderly, et al.
Cancer Cell
|
September 11, 2020
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
Catherine S Grasso, Jennifer Tsoi, Mykola Onyshchenko, et al.
Nature Medicine
|
April 9, 2025
Autologous T cell therapy for PRAME<sup>+</sup> advanced solid tumors in HLA-A*02<sup>+</sup> patients: a phase 1 trial
Martin Wermke, Dejka M Araujo, Manik Chatterjee, et al.
Cancer
|
October 29, 2025
Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938)
Liza C Villaruz, Jingxiao Jin, Hong Wang, et al.
Page
of 19